直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

In Klein Tools v. Milwaukee, the Acting Director Moves Away from the ITC Fintiv Factor Balancing of POSCO

July 3, 2025

Authored and Edited by Forrest A. Jones; *Krista Marrocco

In Klein Tools, Inc. v. Milwaukee Electric Tool Corp., IPR2024-01400, -01401, Paper 22 (PTAB June 9, 2025), the Acting Director intervened on review and denied institution for “erroneous” weighing of the Fintiv factors. In doing so, she seemingly rejected the reasoning of POSCO for how to assess parallel ITC investigations under Fintiv.

Ever since the February rescission of the 2022 Fitniv memo, the PTAB has been grappling once again with how to apply Fintiv to ITC investigations. ITC investigations are different from most parallel litigations considered by the PTAB for two reasons. First, because they typically involve at least two parallel proceedings: a district court action, which is stayed, and an ITC investigation, which is not. And second, because the ITC lacks authority to invalidate a patent, eventually invalidity will be at issue in the stayed district court action. Because of this, how factor 1 (likelihood of a stay) and factor 4 (overlap) should be assessed is not as clear.

As we have previously discussed, one of the leading cases from the APJ merits panels addressing this question is POSCO Co., Ltd. v. Arcelormittal, IPR2024-01376, Paper 11 at 3 (P.T.A.B. March 18, 2025), which answered this question by shifting emphasis from factor 1 to factor 4. By its reasoning (which the panel in Klein Tools adopted), the “overlap” of “patentability disputes” in the ITC tells you whether the district court stay in truth “allays concerns about inefficiency.”

However, in Klein Tools, the Acting Director seemingly rejected this reasoning, finding “[t]he Board’s analysis of factors 1 and 4, and overall weighing of the Fintiv factors were erroneous.” She found that factor 1 weighed against institution because a stay of the ITC proceeding is unlikely, with no mention of the parallel district court proceeding. She also found factor 4 weighed against institution because “the Board [did not] sufficiently consider the extent of the overlap between the two proceedings,” because “the ITC investigation involves the same parties, the same challenged claims, and includes overlapping prior art references.” Additionally, the Acting Director found that the merits under factor 6 did not outweigh the concerns raised by factors 1 and 4.

This decision raises the question whether the holding in POSCO, which is still pending for director review, will be upheld. While the Acting Director’s reliance on error in “weighing” the factors would seem to indicate it may not, this case could also have been decided more narrowly on the error for factor 4, which is “elevated” in importance under POSCO. The POSCO case has been fully briefed for director review for almost two months, so the answer should be forthcoming.

Tags

Fintiv, Patent Trial and Appeal Board (PTAB)

Related Practices

Global IP Enforcement, Litigation, and Trials

ITC Section 337 Investigations and Trials

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Washington, DC

Contacts

Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email

*Krista Marrocco is a Summer Associate at Finnegan.

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 



DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP